HDT-AHCT is a standard curative therapy for patients with relapsed, high risk lymphomas. Severe regimen-related toxicities (SRRT) occur frequently after AHCT, leading to high symptom burden and potentially limiting wider use. The cause of SRRT is thought to be diffuse injury to the organ vascular endothelial niches caused by off-target cytotoxic effects of HDT. Organs with high cell turnover such as oral-gastrointestinal (GI) tract are most affected. The cytotoxic effect impairs the renewal of mucosa, leading to mucositis, nausea, vomiting, and diarrhea. With loss of mucosal integrity, translocation of gut flora into the systemic circulation may lead to life-threatening infections.
AB-205 is an experimental engineered-cell therapy designed to repair damaged tissues and reduce SRRT. AB-205 contains E-CEL® cells: allogeneic E4+ human umbilical vein endothelial cells.
47th European Society for Blood and Marrow Transplantation Annual Meeting – Monday, March 15, 2021
C. Mulroney1, M. Scordo2, M. Abedi3, L.E. Budde4, B. Fakhri5, A. Pawarode6, B. Dholaria7, G. Shouse4, E. Kavalerchik8, S. Aggarwal8, M. Qazilbash9, P. Finnegan8, S. Giralt2
1UCSD Moores Cancer Center, San Diego, United States, 2Memorial Sloan Kettering Cancer Center, New York, United States, 3UC Davis Medical Center, Sacramento, United States, 4City of Hope National Medical Center, Duarte, United States, 5University of California San Francisco, San Francisco, United States, 6University of Michigan, Ann Arbor, United States, 7Vanderbilt University, Nashville, United States, 8Angiocrine Bioscience, San Diego, United States, 9The University of Texas MD. Anderson Cancer Center, Houston, United States
Go to EBMT Meeting – 2021